NattoPharma’s International Research Network has received a €4m grant under the Horizon 2020 programme to study vitamin K2’s role in vascular health.
According to NattoPharma, this funding “will provide training in innovative therapeutic strategies that include MenaQ7, identifying selective targets for microvascular calcification, and its consequences for plaque stability, and provide subsequent strategies for prevention or amelioration of vulnerable plaque formation”.
NattoPharma’s chief medical officer, Hogne Vik, said: “Horizon 2020 grants are the European equivalent to a National Institutes of Health (NIH) grant here in the US.”
The NattoPharma International Research Network is co-ordinated by the Cardiovascular Research Institute at Maastricht University (CARIM), the Netherlands.
The grant, named INTRICARE (International Network for Training on Risks of Vascular Intimal Calcification and Roads to Regression of Cardiovascular Disease) will fund a consortium made up of three research university departments – Universitätsklinikum Aachen, Germany; Karolinska Institutet, Sweden and King’s College, UK – as well as nine small and medium-sized enterprises (SMEs), including NattoPharma.